Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Non-Current Deffered Revenue (2023 - 2025)

Profound Medical has reported Non-Current Deffered Revenue over the past 3 years, most recently at $388000.0 for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $388000.0 for Q4 2025, up 691.84% from a year ago — trailing twelve months through Dec 2025 was $388000.0 (up 691.84% YoY), and the annual figure for FY2025 was $388000.0, up 691.84%.
  • Non-Current Deffered Revenue for Q4 2025 was $388000.0 at Profound Medical, up from $148000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PROF hit a ceiling of $728000.0 in Q4 2023 and a floor of $49000.0 in Q4 2024.
  • Median Non-Current Deffered Revenue over the past 3 years was $116500.0 (2025), compared with a mean of $245333.3.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 93.27% in 2024 and later soared 691.84% in 2025.
  • Profound Medical's Non-Current Deffered Revenue stood at $728000.0 in 2023, then crashed by 93.27% to $49000.0 in 2024, then soared by 691.84% to $388000.0 in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $388000.0 (Q4 2025), $148000.0 (Q3 2025), and $74000.0 (Q2 2025) per Business Quant data.